Page last updated: 2024-08-21

isoxazoles and pelabresib

isoxazoles has been researched along with pelabresib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Cooper, MR; Eda, H; Mertz, JA; Panaroni, C; Raje, N; Ramachandran, J; Santo, L; Sims Iii, RJ; Siu, KT; Yee, AJ1
Arnold, L; Raythatha, J1
Järvenpää, J; Küblbeck, J; Lahtela-Kakkonen, M; Rahnasto-Rilla, M1
Ferreira Gomes, G; Harrison, C1

Reviews

1 review(s) available for isoxazoles and pelabresib

ArticleYear
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
    Current hematologic malignancy reports, 2023, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Benzazepines; Humans; Isoxazoles; Primary Myelofibrosis

2023

Other Studies

3 other study(ies) available for isoxazoles and pelabresib

ArticleYear
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Leukemia, 2017, Volume: 31, Issue:8

    Topics: Animals; Benzazepines; Cell Cycle Proteins; G1 Phase Cell Cycle Checkpoints; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Isoxazoles; Mice; Multiple Myeloma; Nuclear Proteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Transcription Factors

2017
The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.
    Epigenomics, 2019, Volume: 11, Issue:14

    Topics: Benzazepines; Epigenesis, Genetic; Humans; Isoxazoles

2019
Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147

    Topics: Azepines; Benzazepines; Benzodiazepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Isoxazoles; Proteins; Sirtuins; Transcription Factors; Triazoles

2022